

ZIMBABWE

STRATEGIC FOCUS

The U.S. Centers for Disease Control and Prevention (CDC) works closely with Zimbabwe's Ministry of Health and Child Care (MOHCC) to expand the robust national HIV response to reach and sustain epidemic control. CDC Zimbabwe provides technical assistance (TA) and supports program implementation to build Zimbabwe's public health capacity and technical expertise while enhancing the infrastructure required for a high-impact and sustainable HIV response.

Current areas of strategic focus include:

- HIV prevention, testing, and antiretroviral therapy (ART)
- HIV and tuberculosis (TB) screening, treatment, and TB infection control program integration
- Laboratory support for HIV and TB diagnosis and monitoring and optimization of the integrated specimen transport system
- Health systems infrastructure strengthening, including health information systems, public health disease surveillance, capacity building, and quality improvement

KEY ACTIVITIES AND ACCOMPLISHMENTS

Prevention and Case-Finding

CDC supports four DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe) districts with HIV prevention programs for adolescent girls and young women, and supports pre-exposure prophylaxis (PrEP) access in nine districts. As of December 2021, CDC provided technical assistance and support to the MOHCC to successfully conduct 59,740 voluntary medical male circumcisions (PEPFAR program data 2021). CDC and other implementing partners support the MOHCC in providing safe HIV testing services through implementation of the HIV epidemic control focused testing strategy. The models include HIV index contact testing, HIV self-testing, focused testing for high-risk populations and HIV testing as part of clinical services offered during the provision of HIV prevention interventions.

HIV Treatment Program

CDC and other implementing partners collaborate with the MOHCC to expand ART to over 1.1 million Zimbabweans, translating to approximately 89 percent of people living with HIV (PLHIV) across the country receiving ART (PEPFAR program data 2021). This is largely the result of TA, direct human resource support and strong coordination among stakeholders.

Surveys, Surveillance and Program Information

CDC supports the MOHCC to scale-up and roll out HIV case-based surveillance using an Electronic Health Record (EHR) system. The system uniquely identifies patients and reports data in real-time for newly diagnosed and recent infections. By December 2021, 674 facilities were reporting data for all HIV-infected persons. The second Zimbabwe Population-based HIV Impact Assessment was completed in 2020. Results show Zimbabwe met the UNAIDS' 2020 Fast-Track second 90 (97 percent on ART) and third 90 (90.3 percent have suppressed viral load (VL) goals) showing good progress towards achieving epidemic control. CDC supports the 2030 goals of 95-95-95: 95 percent of all PLHIV will know their HIV status; 95 percent of all people with diagnosed HIV will receive sustained ART; and 95 percent of all people receiving ART will have viral suppression.

Tuberculosis (TB)/HIV

CDC is collaborating with the MOHCC's AIDS and TB Unit and implementing partners to scale-up TB preventive treatment for all eligible clients, including rolling out newer regimens. CDC supports implementation of targeted universal testing for TB to improve TB case detection among PLHIV.

Laboratory Support

CDC partners with the MOHCC to strengthen universal access to VL testing for all people on treatment. According to PEPFAR Program data, 678,038 patients had accessed a VL test by December 2021. Strategies to increase access to VL testing include optimization of the Integrated Sample Transportation system, Clinic Laboratory Interface and result management through the Laboratory Information Management System (LIMS), and SMS messaging result relay system. CDC plans to accelerate the integration of LIMS and EHR.

Key Country Leadership

President:
H.E. Emmerson Mnangagwa

Minister of Health:
V.P. Constantino Chiwenga

Charge d'Affaires:
Elaine French

CDC/DGHT Director:
Dr. Michael Melchior

[Country Quick Facts](https://worldbank.org/en/where-we-work)
(worldbank.org/en/where-we-work)

Per Capita GNI:
\$1,400 (2021)

Population (millions):
15.09 (2021)

Under 5 Mortality:
54/1,000 live births (2020)

Life Expectancy:
62 years (2020)

[Global HIV/AIDS Epidemic](https://aidsinfo.unaids.org)
(aidsinfo.unaids.org)

Estimated HIV Prevalence
(Ages 15-49): 11.6% (2021)

Estimated AIDS Deaths
(Age ≥15): 17,000 (2021)

Estimated Orphans Due to
AIDS: 550,000 (2021)

Reported Number
Receiving Antiretroviral
Therapy (ART) (Age ≥15):
1,136,246 (2021)

[Global Tuberculosis
\(TB\) Epidemic](https://who.int/tb/country/data/profiles/en)
(who.int/tb/country/data/profiles/en)

Estimated TB Incidence :
193/100,000 population
(2020)

TB patients with known HIV
status who are HIV-positive:
54% (2020)

TB Treatment Success Rate:
84% (2019)

DGHT Country Staff: 38
Locally Employed Staff: 31
Direct Hires: 6
Fellows & Contractors: 1

Our success is built on the backbone of science and strong partnerships.

September 2022 | The CDC Division of Global HIV & TB activities are implemented as part of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); non-HIV related TB activities are supported by non-PEPFAR funding

